<DOC>
	<DOCNO>NCT00715689</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial investigate safety , tolerability , pharmacokinetics pharmacodynamics NNC126-0083 growth hormone deficient adult</brief_summary>
	<brief_title>Dose Study Growth Hormone Deficient Adults Investigating Safety , Pharmacokinetics Pharmacodynamics NNC126-0083</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>GHDA subject define Consensus guideline diagnosis treatment adult GH deficiency II Fertile female must agree use appropriate contraceptive method negative pregnancy test inclusion GH replacement therapy 3 month Body Mass Index ( BMI , kg/m2 ) 22.0 35.0 kg/m2 , inclusive Females childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method Malignant disease Proliferative retinopathy judge retinaphoto within last year concomitant diabetes Heart insufficiency , NYHA class great 2 Subjects diabetes HbA1C 8.0 % Diabetic receiving insulin treatment Stable pituitary replacement therapy le 3 month Impaired liver function Impaired kidney function</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>